The excitement around Cisco’s latest SD-WAN bugs has inspired some light fraud, misunderstandings, and overlooked risks.
Roivant CEO, bullish on internal growth, dodges M&A chatter
These days, if you ask the CEO of Roivant if he’s open to selling another late-stage drug to a larger company, he refers you to a spoof video clip. It’s the scene from “Toy Story” …
Effect of a Digital-Driven Physician-Pharmacist Collaborative Model for Diabetes in Primary Health Care: Cluster Randomized Trial
Background: Evidence-based physician-pharmacist collaborative clinics have demonstrated significant short-term benefits for patients with type 2 diabetes (T2D), but their long-term effectiveness remains unclear, especially in primary health care settings. Objective: This study aimed to explore the long-term effectiveness and cost-effectiveness of a novel, digital-driven, multifaceted physician-pharmacist collaborative model for managing patients with T2D in underresourced […]
The Performance of Artificial Intelligence in Classifying Molecular Markers in Adult-Type Gliomas Using Histopathological Images: Systematic Review
Background: Adult-type gliomas are among the most prevalent and lethal primary central nervous system tumors, where prompt and accurate diagnosis is essential for maximizing survival prospects. Molecular classification, particularly the detection of isocitrate dehydrogenase (IDH) mutations and 1p/19q codeletions, has become crucial for accurate diagnosis and prognosis. Artificial intelligence (AI) has emerged as a promising […]
The Data Gap: Why Nonprofit Cyber Incidents Go Underreported
Threat actors target nonprofits due to security gaps and highly coveted information, but a lack of sufficient data makes it difficult to grasp the entire picture.
Cyberattackers Don’t Care About Good Causes
Sightline Security’s founder and advisory board discuss how cybersecurity poses significant problems for nonprofits and suggest ways the industry can help.
Will AI Save Consumers From Smartphone-Based Phishing Attacks?
Sophisticated phishing attacks are bypassing on-device protections with troubling frequency, making it more critical than ever for users to protect themselves from potential threats, new research from Omdia shows.
Gubra plots Roivant-like model as partnered obesity drugs take flight
A 300-employee Danish biotech is evolving beyond its obesity partnerships and looking to adopt an incubation model that has served Roivant Sciences quite well over the years. Gubra, the 18-year-old biotech that planted the seed …
Why physical AI is becoming manufacturing’s next advantage
For decades, manufacturers have pursued automation to drive efficiency, reduce costs, and stabilize operations. That approach delivered meaningful gains, but it is no longer enough. Today’s manufacturing leaders face a different challenge: how to grow amid labor constraints, rising complexity, and increasing pressure to innovate faster without sacrificing safety, quality, or trust. The next phase […]
Immutep’s LAG-3 drug fails Phase 3 lung cancer study
A few years ago, the oncology world wondered if it had found its next big breakthrough: a third major checkpoint inhibitor beyond PD-1 and CTLA-4. The FDA in 2022 …
Ultragenyx’s gene therapy hits key endpoint in Phase 3 trial for blood ammonia disease
Ultragenyx said its gene therapy candidate for a rare metabolic disease has hit one of two primary endpoints in a late-stage study. The drug is being tested in 37 people with ornithine transcarbamylase deficiency, a …
Regenxbio, Solid report data with Duchenne gene therapies
Regenxbio and Solid Bio say their gene therapies for Duchenne muscular dystrophy show no sign so far of the liver issues seen with Sarepta’s Elevidys.